Atlas Trials

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Clinical trial NCT05504720 · COMPLETED

Trial details

NCT number
NCT05504720
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Esophagogastric Adenocarcinoma
Start date
2023-02-13
Primary completion
2026-07-15
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.